CAS: 490039-72-0; 4-Iodonicotinonitrile

相似化合物

1061357-83-2 1061357-87-6 15366-63-9

上下游产品

pyridine-3-carbonitrile 7-aza-1,2,3,4,4a,9a-hexahydro-1,4-methanofluoren-9-one 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrido[4,3-d]pyrimidin-4-amine

📜3-氰基吡啶置于2,2,6,6-四甲基哌啶,正丁基锂,碘体系中,用 四氢呋喃,正己烷 作为反应溶剂,化学反应 1.5H,以56%的收率获得产物3-氰-4-碘吡啶
参考文献:Straightforward Access To Ethyl 3-Aminofuropyridine-2-Carboxylates From 1-Chloro-2-Cyano-Or 1-Hydroxy-2-Cyano-Substituted Pyridines
标题:Straightforward Access To Ethyl 3-Aminofuropyridine-2-Carboxylates From 1-Chloro-2-Cyano-Or 1-Hydroxy-2-Cyano-Substituted Pyridines
摘要:描述并详细讨论了合成四种乙基3-氨基呋喃吡啶-2-羧酸酯的条件.起始材料为1-氯-2-氰基吡啶或1-氰基-2-羟基吡啶.
DOI:10.1055/s-2007-990810

专利信息

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).